BUSINESS
Claris Lifesciences net cash stands at Rs 381 per share, stock down 7.46%
Drug maker Claris Lifesciences said its net cash availability stands at Rs 2077 crore translating to Rs 381 per every single share, without considering taxes.
BUSINESS
Sun Pharma gets EIR for Dadra formulation facility
Dadra is the company’s second largest USFDA-approved plant after Halol with several pending generic filings. Analysts estimate the Dadra formulation plant to generate USD 250 million in annual sales.
TRENDS
Pharma stocks rebound, Natco's Copaxone US nod highlight of the week
Pharma stocks recovered this past week on a spate of new approvals in US and news of near normalization in September of domestic formulation business after disruption caused in the month ahead of GST roll out.
BUSINESS
Profits from Copaxone generics to help strengthen balance sheet, expansion: Natco CEO
Natco Pharma said it plans to utilize the cash flows generated by the launch of generic versions of Israel-based Teva’s top selling multiple sclerosis Copaxone 20 mg/ml and 40 mg/ml by its partner Mylan in US towards strengthening balance sheet and investing on business expansion.
BUSINESS
Mylan launches copy of Copaxone 40 mg even as patent litigation is on
The launch comes as analysts were debating whether Mylan would wait till the outcome of pending patent ligation or it will go ahead and launch “at risk”.
BUSINESS
Intas claims its new cancer drug is 60% cheaper than rivals in India
The drug has been available in India since 2004 but the cost has been so prohibitive that eminent clinicians in the country say they have only been able to give this drug to very few eligible patients.
BUSINESS
Teva warns Mylan of 'significant damages' if it goes ahead with the launch of Copaxone 40mg copy
Teva said it will do its best to defend its patent claims over the Copaxone 40mg/ml version and is prepared to face generic competition.
BUSINESS
Natco readies for windfall gain after US FDA okays Copaxone copies
The much anticipated approval has the potential to generate a massive windfall to the company. Even by conservative estimates analysts expect Natco to rake in profits in excess of Rs 1000 crore from the two generic versions in the coming quarters.
BUSINESS
ICMR chief Soumya Swaminathan to be WHO's new Deputy Director General
The 58-year-old Swaminathan, a pediatrician and a clinical scientist known for her research on Tuberculosis (TB). Most recently, Swaminathan was Secretary of the Department of Health Research and Director General of the Indian Council of Medical Research (ICMR).
BUSINESS
Indian drugmakers' revenue growth in US may cool off to 7-10% over 3 years: ICRA
Indian drug makers’ revenue growth in US may cool off to 7-10 percent over the next three years after mid- to high double-digit growth over the last five years owing to rising competition.
BUSINESS
Pharma wrap: Divis takes a hit, govt restricts stent makers from pulling out
A round-up of the top stories from the pharma sector.
BUSINESS
Glenmark says specialty & innovative products to contribute 30% revenues by 2025
Glemark said it hopes to generate 30 percent of its revenues by 2025 from specialty and innovative products alone. To invest on specialty and innovative pipeline Glenmark said its R&D expenses will stay at roughly 11 – 12 percent of revenues.
BUSINESS
DoP invokes emergency powers to block stent makers from withdrawing products
The Section 3 of DPCO allows the government in emergency cases to direct any manufacturer to ensure adequate availability of drugs or devices.
BUSINESS
NPPA allows Abbott Healthcare to withdraw its popular drug eluting stent
Abbott earlier this month approached NPPA seeking to discontinue sale of its Xience Alpine stent from India citing lack sales viability following capping of prices of medical devices by the drug price regulator early this year.
BUSINESS
Cadila Healthcare enters pact with Pharm-Aid to produce Chickenpox vaccine in Russia
Through this agreement, Zydus gains access to the public and private market segments in the Russian Federation, Belarus, Uzbekistan, Kazakhstan, Armenia and Kyrgyzstan, Cadila Healthcare said in a statement.
BUSINESS
Govt to come up with a universal health insurance soon, consultations on with stakeholders
Providing universal healthcare has been promise of the Narendra Modi government, but the progress has been patchy.
BUSINESS
Biocon's Vizag API plant clears US FDA inspection, shares up
Biocon on Monday said it received zero observations for its active pharmaceutical ingredient (API) plant in Visakhapatnam, Andhra Pradesh.
BUSINESS
Pharma weekly wrap: Pharma stocks gain on investor interest due to cheap valuations
The BSE Healthcare rose 4.44 percent in the past week, the benchmark Sensex gained 1.49 percent
BUSINESS
Timeline of Dr Reddy's regulatory issues and stock price movement
The latest jab is a part of the never-ending saga of regulatory compliance woes the company has been facing starting November 2015
BUSINESS
Law to check unethical marketing practices in pharma faces delay due to legal tangle
The Law Ministry, which was vetting UCPMP, asked the DoP to rework on the draft code as it wasn’t aligned with the legal framework of Essential Commodities Act.
BUSINESS
Biocon gets funding from JDRF to test oral insulin on type-1 diabetes patients
As per the agreement – JDRF or Juvenile Diabetes Research Foundation as it was known will fund Biocon’s global multiple ascending dose study of oral insulin drug candidate to evaluate the safety and tolerability in people with type 1 diabetes.
BUSINESS
No change in IPO plans: Aster DM Healthcare set to refile DRHP
Aster DM Healthcare filed its draft red herring prospectus (DRHP) for IPO in June 2016 with an intention to raise around Rs 2,000 crore, to provide an exit to existing PE investors, repay debt, and invest on expansion.
BUSINESS
Dr Reddy's gets two USFDA observations for Srikakulam plant
The company said was addressing the observations raised by US FDA without specifying the nature of those observations.
BUSINESS
Dishman Pharma gains 20% on US FDA nod to client's cancer drug
"We believe that the increase in the stock price is based upon market estimation that we are one of the suppliers of the API for Zeluja capsules, which got approved by the US FDA," the company said in clarification to stock exchanges. Dishman however did not confirm whether it is the API supplier for Tesaro's Zeluja citing confidentiality agreements.
